A licensed clinician is essential for determining the correct starting dose, making adjustments based on your progress, and monitoring your overall health
No additional active drugs are included
Singh, P., Vinikoor, T., Sharma, N., Nelson, N., Prasadh, S., Oiknine, R., & Nguyen, T
Treatments last approximately 30 minutes and can be repeated based on individual needs
Regulatory and compounding status All four compounds share a broadly similar regulatory landscape in the United States as of 2026: None are FDA-approved as finished drug products for therapeutic use All are classified as WADA S2 prohibited substances year-round All four have 503A compounding status of Under Review, meaning the FDA Pharmacy Compounding Advisory Committee (PCAC) has nominated them for evaluation but final category assignments (Category 1 permitted for compounding